Syngenta and Amoéba sign exclusive European biofungicide deal
Syngenta Crop Protection and French biotech Amoéba have converted a November 2025 memorandum of understanding into a binding, long-term supply and distribution agreement covering a next-generation biocontrol fungicide designated AXP20. Syngenta holds exclusive distribution rights for all cereals except corn across the EU-27, the United Kingdom, Ukraine and Switzerland. First market registrations are targeted for Q3 2028, with initial sales in core EU markets expected by year-end 2028, ahead of grower use in spring 2029.
The active substance, the lysate of the single-celled amoeba Willaertia magna C2c Maky, received European Union approval in 2025 following an assessment by the European Food Safety Authority. In June 2026, Amoéba received a marketing authorisation in France for its AXPERA product, based on the same organism. That approval is intended to accelerate national registrations across other member states. No financial terms for the distribution deal were disclosed in the announcement.
What makes AXP20 different
The product's commercial case rests on its biological origin and a resistance profile that separates it from conventional synthetic fungicides. It works primarily by inhibiting the germination of fungal spores and is reported to stimulate plant defence mechanisms as a secondary effect. The Fungicide Resistance Action Committee classifies it under Group BM02, biologicals with multiple modes of action, with no known resistance and a low-to-very-low resistance risk. That classification matters commercially: conventional fungicide classes face mounting resistance build-up in European cereal pathogens, and regulators have progressively withdrawn active substances from the market.
The two diseases AXP20 primarily targets, septoria tritici blotch and yellow rust, are described by the partners as the most economically damaging fungal threats in European cereals, affecting an estimated 9 to 12 million hectares annually. According to figures the companies attributed to industry and academic sources, septoria alone costs German farmers up to 1.5 billion euros per year. Matthew Pickard, Syngenta's head of seedcare and biologicals for Europe, said the product "arrives at exactly the right moment" for growers looking to protect yields as conventional options diminish.
Market and policy context
The European biocontrol market has expanded steadily as the EU's Farm to Fork strategy and successive pesticide review processes have accelerated the withdrawal of conventional active substances, creating commercial space for biological alternatives. Syngenta, BASF, Corteva and a cluster of specialist developers including Koppert and Marrone Bio Innovations have all built or acquired biologicals pipelines in recent years. The competitive pressure is on registration timelines and field-trial validation rather than on feedstock or manufacturing cost, which are the binding constraints in most cleantech categories.
For Amoéba, listed on Euronext Growth, the Syngenta agreement represents a route to scale that would be difficult to achieve independently. Syngenta's existing distributor relationships across European cereal markets remove a substantial commercial barrier. The partners say they are jointly running more than 70 field trials in 2026 to validate efficacy and support national registration dossiers, positioning AXP20 as one of the more extensively trialled new biocontrol products entering the European regulatory pipeline.
The EU's renewed Sustainable Use of Pesticides Regulation, currently under revision, is the primary policy variable. Tighter reduction targets for synthetic pesticide use would sharpen demand for registered biocontrol alternatives, but the pace of that legislative process remains uncertain after earlier proposals were delayed. Growers and distributors are meanwhile facing the 2028 registration window, which leaves limited time for unexpected regulatory setbacks before the targeted first-sale date.